INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

Transcriptional activation of class II genes by RNA polymerase II (RNAPII) involves protein-protein interactions between transcriptional activators and their coactivators (50). One extensively studied group of coactivators is the p300/CREB binding protein (CBP) family (72). p300 and CBP are distinct proteins encoded by two different genes and were initially identified independently (13, 18, 81). However, these two proteins not only share significant homology in their functional domains but also mediate transcription by binding to similar sets of transcriptional activators (72). Both can be negatively regulated by the 12S form of adenovirus E1A (2, 4, 56). Thus, these proteins are often referred to as p300/CBP. There are a variety of p300/CBP-interacting transcriptional activators, including CREB (44), c-Jun (46), ATF-2 (39), nuclear receptors (11, 34, 85), MyoD (87), SREBP-2 (64), and YY1 (47), suggesting that p300/CBP may play an integrating role in different cellular events mediated by these activators, such as cell proliferation, differentiation, and signaling (70, 72, 86). Interestingly, p300/CBP also binds to the p53 transcription activator and stimulates p53-dependent transcriptional activity in vivo (3, 26, 51), indicating that this group of coactivators also participate in the p53 response pathway.

The transactivation activity of the p53 tumor suppressor protein is important for regulating cell growth and apoptosis in response to various cellular stress signals (23, 42, 48, 49). This activity is contributed by three main domains of this protein: the N-terminal transactivation domain (amino acids [aa] 1 to 45) (21, 67), the central sequence-specific DNA binding domain (aa 113 to 290) (6, 12, 66, 80), and the C-terminal regulatory region (30). The N terminus contacts several transcriptional regulators, including components of the RNAPII transcriptional machinery, such as TAF_II31 and TAF_II70 (54, 75), and the coactivators p300 and CBP (3, 26, 51). Phosphorylation of this domain at Ser15 regulates the activity and stability of p53 in response to DNA damage (71, 73). The central sequence-specific DNA binding domain recognizes and binds to a specific consensus sequence with two copies of the 10-mer 5'-RRRC(A/T)(T/A)GYYY-3' (19), which has been identified in many p53 target genes (76). The products of these genes, including p21^waf1 (17, 20), MDM2 (82), Gadd45 (36), BAX-1 (59), IGF-BP3 (10), and 14-3-3 (29), act as downstream effectors of the p53-mediated growth arrest or apoptosis. The C terminus regulates p53 transcriptional activity (30). Posttranslational modification of this region, such as DNA damage-responsive phosphorylation (35, 55) or acetylation (25, 53, 68), leads to activation of p53's DNA binding and transcriptional activities. Because of its crucial importance in cell growth regulation, the transcriptional activity is conserved among p53 homologs.

Several p53-like proteins have been reported recently. One gene, designated the p73 gene, has been isolated and found to encode two spliced polypeptides, p73 and p73. p73 (499 aa), possessing a unique pentamer at its extreme C terminus, is 137 aa shorter than p73 (636 aa) (33). The p73 protein resembles p53 in both sequence (approximately 60% identity with p53 in the central domain and 29% identity in the N terminus) and function (31, 33). Like p53, p73 transactivates p53 target genes in vivo and causes apoptosis and growth suppression (31, 33). Although p73 was expressed monoallelically in neuroblastoma, its tumor suppression function remains uncertain, because only the wild-type form has been identified in all tumors or tumor cell lines tested (33). Another group of p53 homologs, p51/p63 (65, 69, 77, 83), was also identified and found to share 55 to 65% homology with p53 in the central domain. These p53 homologs can also suppress cell growth, induce apoptosis, and transactivate p53-responsive genes (65, 83), although it is unclear whether they suppress tumor growth. Finally, two additional p53-like activities have been identified, p53-competing protein from mouse (9) and NBP (non-p53 response element [p53RE] binding protein) from human (90) cell lines, although their identity remains to be clarified. Thus, the transcriptional function is well conserved in the p53 family.

Identification of multiple p53 homologs suggests that these proteins have distinct roles during embryogenesis and development or in response to different cellular signals. In fact, two recent p63 knockout studies demonstrated that p63, in contrast to p53 (16), is essential for limb and epidermal morphogenesis (58, 84). Also, unlike p53, p73 was not induced by some DNA damage signals (33), suggesting a distinct pathway for this protein. Indeed, p73 has recently been shown to be activated through c-Abl-mediated tyrosine phosphorylation in response to DNA damage caused by cisplatin or  but not UV irradiation (1, 22, 89). Because of the lower level of homology between p53 and p73 in the N and C termini (33), it would be interesting to learn whether these transcriptional activators interact with the same set of coactivators, such as p300/CBP, or with the same domains of these coactivators. It is clear that different domains of p300/CBP mediate transcription and thus signaling by different transcriptional activators (72). Hence, identifying p73-interacting proteins or domains of the proteins would provide clues for the potential signaling of p73. In attempt to address this issue, we have investigated whether p300 and CBP regulate p73-dependent function. We found that p300/CBP bound to p73 both in vitro and in vivo and that it enhanced p73-dependent transcription. Functional mapping revealed that unlike p53 (3, 26, 51; X. Zeng and H. Lu, unpublished data), p73 through its the N terminus utilized the N-terminal CH1 domain (aa 390 to 450) of p300/CBP for transcriptional activation and apoptosis. Consistent with this observation, p73 functions were found to be impaired to different degrees in p300- and CBP-deficient cells. Thus, this study provides evidence that p73 interacts with the N-terminal domain of p300/CBP to execute its transcriptional function.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Plasmids and antibodies. The pCDNA3-HA-p73 and pCDNA3-HA-p73 plasmids were obtained from William G. Kaelin, Jr. (Dana-Farber Cancer Institute, Boston, Mass.). pCDNA3-Flag-p300 or CBP plasmids were constructed. pCMV-p300-Ha was obtained from David Livingston (Dana-Farber Cancer Institute). pGSTCBP1(aa 390-790) and pGSTCBP3(aa1990-2441) were obtained from Robert G. Roeder (Rockefeller University, New York, N.Y.). pGST-p300(aa 1571-2414) was a gift from Yang Shi (Harvard Medical School, Boston, Mass.). pCDNA3-N-p73 was constructed by PCR-directed mutagenesis using pCDNA3-HA-p73 as a template. pCNA3-GFP, encoding green fluorescent protein (GFP), was a gift from Moshe Oren (Weizmann Institute, Rehovot, Israel). pCDNA3-Flag-p73 was constructed by putting a Flag epitope in front of this insert. pEGFP-C1 was purchased from GIBCO-BRL. The monoclonal anti-p73 antibodies ER15, recognizing both p73 and p73, and ER13, recognizing only p73, were generously provided by William G. Kaelin, Jr. (57). Polyclonal anti-CBP antibodies recognizing both p300 and CBP were raised against the N-terminal region of CBP from aa 350 to 550. Monoclonal anti-p300 antibodies against the C-terminal domain of p300 were purchased from Upstate Biotechnology. Polyclonal anti-p53 antibodies were purchased from Santa Cruz Biotechnology. A monoclonal anti-p73 antibody against the C terminus of this protein was purchased from Oncogene.

Buffers. Lysis buffer consisted of 50 mM Tris-HCl (pH 8.0), 0.5% NP-40, 1 mM EDTA, 150 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride. SNNTE buffer contained 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 1% NP-40, 500 mM NaCl, and 5% sucrose. Radioimmunoprecipitation assay (RIPA) buffer consisted of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), and 1% (wt/vol) sodium deoxycholate. Buffer C 100 (BC100) included 20 mM Tris-HCl (pH 7.9), 0.1 mM EDTA, 10% glycerol, 100 mM KCl, 4 mM MgCl₂, 0.2 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol (DTT), and 0.25 µg of pepstatin A/ml.

Cell culture. Human cervical carcinoma HeLa, human osteosarcoma Saos-2, and small-cell lung carcinoma H1299 cells were cultured in Dulbecco's modified Eagle medium supplemented with 5 to 10% fetal bovine serum, 50 U of penicillin/ml, and 0.1 mg of streptomycin/ml at 37°C in a 5% CO₂ atmosphere. p300- or CBP-deficient H1299 or human breast carcinoma MCF-7 cell lines were cultured in the same medium except that G418 (0.4 µg/ml) was added as a selection marker as previously described (88).

Construction and preparation of GST-p300 and GST-p73 fusion proteins. The glutathione S-transferase (GST)-p300 fusion protein expression plasmids were constructed as previously described (87). The GST-p73 fusion protein expression vectors were made by inserting the PCR-generated fragments of p73 into pGEX-KT (Pharmacia) at the EcoRI sites. The orientation and sequence of each p73 fragment were confirmed by sequencing and Western blotting (WB). These GST fusion proteins were expressed in and purified from bacteria. The GST-p73 (aa 411 to 636) fusion protein was also used as an antigen for generation of polyclonal anti-p73 antibodies as described above.

Preparation and fractionation of HeLa cell nuclear extracts. Nuclear extracts were prepared from HeLa cells as described elsewhere (14). Briefly, 30-ml aliquots of nuclear extracts containing 10 mg of protein/ml (~5 × 10⁹ HeLa cells) were fractionated through a phosphocellulose (P11) column as described previously (54). Proteins were eluted by stepwise washes with 0.1, 0.3, 0.5, and 1.0 M KCl-containing buffer C.

Coimmunoprecipitation and WB analyses. Fifty-microliter aliquots of the 0.3 M protein fractions from the P11 column were incubated at 4°C for 4 h with 30 µl of protein A-agarose and 1 µg of antibodies specifically against p300 (monoclonal) and p73 (polyclonal). The beads were washed as described above. Bound proteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and analyzed by WB as described elsewhere (54), using the same antibodies, preimmune serum, or antibody 419 as a control, and detected by enhanced chemiluminescence (Amersham).

Purification of Flag-p300 and Flag-CBP. Flag-p300 and Flag-CBP were purified from a baculovirus expression system by immunoaffinity chromatography (27, 54) and used for protein association assays described below.

Transfection and coimmunoprecipitation. H1299 cells (three 60-mm-diameter plates) were transfected with 3 µg of the parental pCDNA3, p73-HA, or p73-HA expression plasmid by means of LipofectAmine (GIBCO-BRL). Six hours after transfection, fresh Dulbecco's modified Eagle medium was added to the plates to replace the medium containing plasmids. Cells were harvested 48 h posttransfection. Cell lysates were prepared as described previously (55). Lysates (1 mg of proteins) were precleared with 35 µl of protein A-agarose (50% slurry) and then incubated for 3 h at 4°C with fresh protein A-beads (35 µl) and 2 µg of monoclonal antibody ER15, 421, or 419. The beads were loaded directly onto a SDS-acrylamide gel after vigorously washes twice with lysis buffer, twice with SNNTE, and once with RIPA buffer. The coimmunoprecipitated proteins were detected by WB using ER15 or polyclonal anti-CBP antibodies (detecting both p300 and CBP).

Metabolic labeling of cells. H1299 cells (50% confluent) were transfected with plasmids as indicated in the legend to Fig. 1, using LipofectAmine (Promega) as described above. At 32 h posttransfection, cells were metabolically labeled with [³⁵S]Met (1 mCi/60-mm-diameter dish) for 8 h and then harvested for immunoprecipitation; 2 million cpm was used for each immunoprecipitation reaction, carried out as described above.

Cotransfection and CAT assay. Transfections were carried out as described above with H1299 and Saos-2 cells. Totals of 15 and 4 µg of plasmid DNA were used for 100- and 60-mm-diameter plates, respectively. At 48 h after transfection, the transfected cells were harvested for chloramphenicol acetyltransferase (CAT) assays as described previously (82).

Transient transfection and luciferase assay. H1299 cells (60% confluent in a 12-well plate) were transfected with a pCMV--galactoside reporter plasmid (0.2 µg) and a luciferase reporter plasmid (0.2 µg) driven by two copies of the p53RE motif derived from the MDM2 promoter (82), together with a combination of different plasmids (total plasmid DNA = 1 µg/well) as indicated in Fig. 5 and 7, using GenePORTER (Gene Therapy Systems, Inc., San Diego, Calif.). At 48 h posttransfection, cells were harvested for luciferase assays as described previously (41). Luciferase activity was normalized by a factor of -galactosidase activity tested in the same assay.

GST fusion protein association assay. The fusion proteins were expressed in Escherichia coli and purified on a glutathione (GSH)-Sepharose 12B column. Protein-protein association assays were conducted as reported previously (54), using fusion protein-containing beads. The purified and in vitro-translated, ³⁵S-labeled p53 protein or in vitro-translated, ³⁵S-labeled p73 and p73 proteins generated by using TNT kits (Promega) were incubated with the GSH-Sepharose 4B beads (50% slurry) containing approximately 400 ng of GST-p300, GST-CBP, and GST, respectively. One hour after incubation at room temperature, the mixtures were washed once in BC100 containing 0.1% NP-40, twice in SNNTE, and once in RIPA buffer. Bound proteins were analyzed on an SDS-10% gel and detected by WB using the anti-p53 monoclonal antibody 421 to detect p53-GST-CBP interactions and autoradiography to detect interactions of p53 or p73 with GST-CBP or GST-p300. Similar assays were also conducted to map the p300 or CBP binding site on p73, using GST-p73 fusion proteins as described elsewhere (91).

Apoptotic analysis. The analysis was carried out as previously described (91). H1299 or p300- or CBP-deficient cells (10⁵/35-mm-diameter dish) were transfected with a plasmid encoding GFP (0.85 µg of DNA/dish) together with combinations of expression plasmids (total plasmid DNA = 2 µg/dish) as indicated in Fig. 6. Transfected cells in cultures were analyzed under a fluorescence microscope and identified by the presence of green fluorescence. Apoptotic cells were identified by their rounded and shrunken morphology in contrast to the spread-out appearance of nonapoptotic H1299 cells, counted on a blind basis, and presented as a percentage of the total population of fluorescent cells (see Fig. 6).

Caspase 3 assays. H1299 or p300- or CBP-deficient H1299 cells (60% confluent) were transiently transfected with a plasmid expressing p73 or a p73 mutant lacking the N-terminal aa 1 to 56 (Np73). Cells were harvested and lysed 34 h posttransfection for caspase 3 assays according to a protocol provided by PharMingen. The caspase 3 reaction mix contained 20 µM Ac-DEVD-7-amino-4-methyl coumarin (AMC) substrate for caspase 3 (PharMingen), 150 µg of lysates, and 500 µl of protease buffer (20 mM HEPES [pH 7.5], 10% glycerol, 2 mM DTT freshly added); the reaction was conducted at 37°C for 60 min. AMC released from Ac-DEVD-AMC substrates was measured with a spectrofluorometer (Photon Technology International) with an excitation wavelength of 380 nm and an emission wavelength range of 400 to 500 nm.

DNA fragmentation assays. Transfection of H1299 cells was conducted as described above. Floating or attached cells were harvested separately for DNA isolation 38 h posttransfection. Since few floating cells were found in the control, mutant p73-, or p300-alone-transfected dishes, DNA isolated from attached cells was used as a control. DNA fragments were detected by using a DNA ladder detection kit purchased from BioSource International, Inc., Camarillo, Calif.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Association of p73 with p300/CBP in vivo. During purification of NBP, a recently identified p53-like transcriptional activity from HeLa cell nuclear extracts (90), we detected a significant amount of p73 protein by WB with anti-p73 antibodies in the 0.3 M wash fraction from a phosphocellulose column (Fig. 1A, lane 3 [90]). This finding prompted an examination of whether p73 cofractionates with other cellular proteins that may be important for its function. Given that p53 interacts with p300/CBP (3, 26, 51), the same membrane was then probed with polyclonal anti-CBP antibodies, which detect both p300 and CBP (4, 56). p300 and CBP were enriched in the same fraction (Fig. 1A, lane 3), implying that p73 may form a complex with p300/CBP. To examine this possibility, proteins in the 0.3 M fraction of the P11 column were coimmunoprecipitated with monoclonal anti-p300 or anti-p73 antibodies and detected by WB with antibodies against p73 and p300. As shown in Fig. 1B, the p73 protein was specifically coprecipitated by the monoclonal anti-p300 antibody or vice versa (lanes 2 and 3). As a control, the monoclonal anti-simian virus 40 (SV40) T-antigen antibody 419 or preimmune serum did not pull down any proteins detectable by either anti-p73 or anti-p300 antibodies (lanes 1 and 4). This result suggests that p73 can form a complex with p300.

View larger version (44K): [in this window] [in a new window]   FIG. 1.   p73 forms a complex with p300 in vivo. (A) WB analysis of the protein fractions from P11 and DE-52 columns. Twenty-five-microliter aliquots of the fractions as indicated on the top were directly loaded onto an SDS-10% gel for WB analysis with polyclonal anti-CBP antibodies after probing with the monoclonal anti-p73 antibody ER13. NE, nuclear extract; FT, flowthrough; S, protein samples containing the NBP activity from a phenol-Superose column (90), used as a negative control. (B) Immunoprecipitation followed by WB analysis of the p73-p300 complex. Fifty microliters (approximately 20 µg of protein) of the 0.3 M wash fraction of a P11 column was incubated with antibodies as indicated on top. Immunoprecipitation (IP)-WB analysis was carried out as described in Materials and Methods. The membrane was probed with ER15 and anti-p300 antibodies, respectively. 419 is a monoclonal antibody specific for the SV40 T antigen, used as a negative control (also for panel C). PreI, preimmune serum. (C) Immunoprecipitation of the p73-p300 complexes after transient transfection. H1299 cells (50% confluent in a 60-mm-diameter dish) were transfected with plasmids encoding Flag-p300 (F-p300) and/or HA-p73 as indicated at the top; 32 h posttransfection, cells were metabolically labeled with [35S]methionine for 8 h and harvested for immunoprecipitation. p300-p73 complexes were analyzed by immunoprecipitation using monoclonal anti-p73 (p73) or anti-Flag (Flag) antibodies, as indicated. The asterisk denotes the nonspecific bands brought down by mouse immunoglobulin G, as they appeared equally in all lanes. Here and in other figures, positions of molecular weight markers (in kilodaltons) are indicated at the left. The fast-migrating band of the p300 doublet may represent a shortened large fragment of Flag-p300. The result was obtained after a 2-day exposure to X-ray film. The tiny scratch above the Flag-p300 band on lane 2 was a nonspecific spot caused by film exposure. (D) p73, when overexpressed, binds to endogenous p300 or CBP. H1299 cells (6 × 105/60-mm-diameter dish) were transfected with vectors (3 µg) encoding no insert, p73, or p73, as indicated, and harvested for immunoprecipitation with ER15 (lanes 1 to 3) or 421 (lane 4), followed by WB with ER15 and polyclonal anti-CBP antibodies. Each lane represents the result from three dishes of cells (with 30-min exposure to X-ray film).

p73 binds to the N-terminal domain of p300 or CBP. Because p53 was previously reported to bind to the C-terminal domain (aa 1990 to 2441) of p300/CBP (26), we tested whether p73 targets the same region, using GST protein association assays. Equal amounts (1 µg) of GST-p300 fusion proteins coupled to Sepharose 4B resin were incubated with in vitro-translated, [³⁵S]Met-labeled p73 or p73. Bound proteins were analyzed by SDS-PAGE and detected by autoradiography. As shown in Fig. 2A, both p73 and p73 bound specifically to the p300 N-terminal region from aa 19 to 596 (19-596 domain) but not to the other regions of p300 (two top panels). When GST-CBP fusion proteins were incubated with radioactively labeled p73, both  and  forms of p73 were also observed to interact with the CBP N terminus, as shown by a representative result in Fig. 2B for p73. As CBP fragments encompassing aa 1 to 450 (lane 2) and 390 to 790 (lane 3) retained an equivalent amount of p73, the p73 binding site in CBP (or p300) can be ascribed to the region from aa 390 to 450. Indeed, a CBP fragment of aa 350 to 450 was able to bind to p73 (unpublished data). The faster-migrating p73 band in lane 3 of Fig. 2B was due to its comigration with the GST-CBP 390-790 fusion protein on an SDS-gel. As a control, GST alone did not retain a significant amount of the p73 proteins (Fig. 2), nor did the C-terminal domains of CBP or p300 (Fig. 2). These results suggest that both p73 and p73 physically bind to the first C/H domain (potential zinc finger domain) of p300 and CBP. In contrast, p53 bound to both the N- and C-terminal domains of p300/CBP (Fig. 2A, middle panel). Consistent with a previous report (24), the binding of p53 to the N-terminal CH1 region of p300/CBP appears to be not important for its transcription activity, as a transcriptionally inactive 22/23 mutant of p53 also bound to this domain (Zeng and Lu, unpublished data). The binding of p73 to the domain is not due to an adherent property of this region, as it was not the case for TAF_II31 (Fig. 2A, bottom panel), consistent with a recent report (62). Thus, p73 is associated with the N-terminal CH1 domain of p300/CBP.

View larger version (36K): [in this window] [in a new window]   FIG. 2.   p73 and p53 bind to different domains of p300 or CBP. (A) Protein association analyses with in vitro-translated, 35S-labeled p53, p73, p73, and TAFII31. Equal amounts (3,000 cpm) for each of the in vitro-translated, 35S-labeled proteins (indicated on the right) were incubated with 30 µl of GSH-Sepharose 12B beads (50% slurry) bound by GST or GST-p300 deletion mutants (indicated at the top); 50% of the input was directly loaded onto the gel as a control (lane 1). (B) p73 binds to the first C/H domain of CBP. A GST pull-down assay as described above was carried out but with GST-beads containing a series of CBP deletion mutants as indicated; 50% of the p73 input was directly loaded onto the gel (lane 8). These results were reproducible; the same results were obtained in experiments with GST-CBP fusion proteins and p73 (Zeng and Lu, unpublished data).

p300/CBP binds to the N-terminal domain of p73. To map the p300/CBP binding site in the p73 protein, we carried out a similar set of GST pull-down assays using GST p73 fusion proteins. Bound p300 or CBP was analyzed by SDS-PAGE, followed by WB with antibodies against either p300 or CBP. Either p300 (Fig. 3A) or CBP (Fig. 3B) was retained by the GST-p73 fusion protein containing only the N-terminal domain (aa 1 to 70) but not by the C-terminal region of p73 (aa 311 to 636) (compare lanes 3 with lanes 4 and 5). p300 or CBP did not bind to the GST protein alone (lanes 2). Thus, p300 or CBP appears to recognize the N-terminal domain of p73, which shares a 29% identity with the p53 N-terminal 1-58 domain.

View larger version (29K): [in this window] [in a new window]   FIG. 3.   p300 or CBP binds to the N-terminal domain of p73. One hundred nanograms of partially purified p300 (A) or CBP (B) was incubated with different GST-p73 deletion mutants as indicated (1 µg). The bound p300 or CBP protein was detected by WB with anti-p300 or anti-CBP antibodies; 50% of the input was directly loaded onto the SDS-7% gel. The asterisk indicates degraded p300. These results were reproducible.

p300/CBP stimulates p73-dependent transcription in vivo. To determine the functional relevance of the p300/CBP-p73 interaction, we performed a set of transfection and CAT assays using a CAT reporter plasmid containing two copies of p53RE derived from the MDM2 promoter (82). A p53-deficient human osteosarcoma Saos-2 cell line was cotransfected with 100 ng of p73, p73, or p53 and increasing amounts of p300 or CBP. Since p73 and p73 displayed similar transcription activities in this assay, a representative result for only p73 in contrast with p53 is shown in Fig. 4A. The p73-dependent CAT activity in the presence of 3 µg of the p300 or CBP plasmid was ~10-fold greater than that in the absence of plasmid (Fig. 4A, compare lane 2 with lanes 4 and 6). This stimulation was due to p300 or CBP, as it was not observed when a parental vector was used (Fig. 4A); also, p73 was equivalently expressed regardless of whether p300 or CBP was coexpressed (Fig. 4B, lanes 1 to 6). Moreover, transcriptional activity was specific for p73, as it disappeared when p73 mutant R292H, which is equivalent to the inactive p53 mutant R273H (31), was used in the assay (Fig. 4C). The transcriptional activity of p53 was enhanced, as expected, in the presence of exogenous p300 or CBP (Fig. 4A and B), consistent with previous studies (3, 26, 51). These results were also reproducible using H1299 cells devoid of the p53 protein (Zeng and Lu, unpublished data). We additionally observed that p73 or p53 requires a full-length p300 or CBP protein for synergistic activation of transcription, as p73 or p53 binding fragments of both proteins were unable to enhance p73- or p53-mediated transcription in vivo (Fig. 5E and data not shown). Thus, these studies demonstrate that the coactivators p300 and CBP not only bind to p73 but also enhance transcription mediated by this transcriptional activator.

View larger version (38K): [in this window] [in a new window]   FIG. 4.   p300 or CBP enhances the p73-dependent transcription in vivo. (A) p300 or CBP stimulates p73- or p53-dependent CAT activity in transient transfection-CAT assays. Saos-2 cells (105/60-mm-diameter plate) were transfected with 0.2 µg of the BP100-CAT reporter vector containing two copies of p53RE derived from the MDM2 promoter (82), 100 ng of p73 or p53, together with 1.5 or 3 µg of p300- or CBP-expressing vector, respectively, as indicated. CAT assays were carried out 48 h posttransfection. Fold increase in CAT activity compared with that of the mock transfection is shown at the bottom. CAT activity from three experiments was quantified with a molecular imager (Bio-Rad) and presented as a graph. Vectors without an insert were used as controls. Bars denote fold increase in CAT activities, and standard deviations are indicated at the top of each bar. A similar result was obtained with p73. (B) Expression of HA-p73 or p53, detected by immunoprecipitation with ER15 for HA-p73 or with 421 for p53, followed by WB with 12CA5 for HA-p73 or polyclonal anti-p53 antibodies. Lane 1, control. Lanes 2 to 6 correspond to columns 4 to 8 in panel A, and lanes 7 to 11 match columns 11 to 15 in panel A. Cells from three 60-mm-diameter dishes were collected for each lane. (C) p300 stimulates wild-type but not mutant p73-dependent transcription. The assay described above was conducted with 100 ng of p73 or an inactive p73 mutant R292H. All experiments were repeated three times using Saos-2 and H1299 cells with similar results.

View larger version (45K): [in this window] [in a new window]   FIG. 5.   The N-terminal deletion mutant of p73 is defective in p300 binding and transcriptional activation. (A) The N-terminally deleted mutant of p73 does not bind to p300. Three microliters of in vitro-translated and 35S-labeled wild-type or N-terminally deleted mutant p73 (lacking aa 1 to 56), as indicated at the top, were incubated with Flag-p300 (200 ng). Bound proteins were coimmunoprecipitated by anti-Flag antibodies and detected by autoradiography. (B) The N-terminally deleted mutant of p73 does not bind to the N-terminal domain of p300 in vitro. Three microliters of in vitro-translated and 35S-labeled wild-type or N-terminally deleted mutant p73 were incubated with different GST-p300 fusion proteins as indicated at the top. Bound proteins were analyzed by SDS-PAGE and detected by autoradiography. Lanes 1 and 2, 100% input of wild-type (p73) and mutant (N-p73) proteins, respectively; lane 3, molecular weight markers; lanes 4 through 12, results with N-terminally deleted mutant p73; lanes 13 and 14, positive controls with wild-type p73. (C) The N-terminally deleted mutant of p73 is inactive in transcriptional activation. H1299 cells (105/60-mm-diameter plate) were transfected with plasmids (total, 3 µg of DNA) encoding no gene, p73, or N-p73 (1 µg) together with a luciferase reporter plasmid (0.2 µg) driven by the p53RE motif derived from the p21 promoter and a -galactosidase reporter plasmid (0.2 µg) driven by a cytomegalovirus promoter; 48 h posttransfection, cells were harvested for luciferase (Luc.) and -galactosidase assays. Luciferase activity was normalized by a factor of the internal -galactosidase activity. Fold increase in luciferase activity was calculated and is presented in the graph (each column is from three independent assays, and bars show standard deviations). The bottom panel shows expression of p73 or N-p73 detected by immunoprecipitation with anti-p73 antibodies (Santa Cruz), followed by autoradiography, after in vivo [35S]Met metabolic labeling of the transfected cells. (D) N-p73 lacks transcriptional activity and its potential to cooperate with p300 in transcription. Transient transfection-luciferase assays similar to that in Fig. 5C were carried out except that H1299 cells grown to 60% confluence in 12-well plates were transfected with total plasmid DNA of 1 µg (per well) including 0.1 µg of the luciferase reporter plasmid, 0.1 µg of -galactosidase reporter, 0.1 µg of p73 or N-p73 alone, and 0.35 or 0.7 µg of p300, as indicated. Each column represents a result from triplicate assays. (E) The CH1-containing fragment of p300 inhibits p73-mediated transcription in vivo. H1299 cells were transfected with a p73 expression plasmid (0.1 µg) in the presence or absence of a plasmid (0.7 µg) encoding p300 or a deletion mutant of p300 (one including the fragment from aa 19 to 597, one without aa 242 to 1700, and one with deletion of aa 1700 to 1941) as described for panel D.

The N-terminally deleted mutant of p73 is defective in binding to the N terminus of p300 and stimulating transcription and apoptosis in vivo. The interaction of the N terminus of p73 with p300/CBP suggests that the N terminus of p73 may serve as transactivation domain, though this domain shares a low degree homology (29% identity) with that of p53 (33). To test this possibility, we first examined the direct binding of the p73 N terminus to the N-terminal domain of p300. For this purpose, we generated Np73 and analyzed its interaction with wild-type or mutant forms of p300 by in vitro coimmunoprecipitation and protein-protein association assays. Consistent with the results in Fig. 1 to 3 and our recent report (91), p73 was coimmunoprecipitated with Flag-p300 by anti-Flag antibodies (Fig. 5A, lane 4). However, Np73 was unable to bind to p300 (compare lane 4 with lane 5), indicating that the N-terminal 1-56 domain directly interacts with p300. The interaction was specific, as no signals were immunoprecipitated by anti-Flag antibodies either in the absence of Flag-p300 or using polyclonal antibody 419 specifically against the SV40 T antigen (lane 3 or 6). This interaction was mediated by the N-terminal domain of p300, as binding of Np73 to the N-terminal region (aa 19 to 596) of p300 was dramatically reduced compared with that of the wild-type p73 (Fig. 5B, compare lane 6 with lane 13). These results demonstrate that the N terminus of p73 directly binds to the N-terminal CH1-containing domain of p300.

View larger version (52K): [in this window] [in a new window]   FIG. 6.   p300 enhances p73-induced apoptosis. (A and B) The N-terminal deletion of p73 lacks apoptosis-promoting potential. As indicated, plasmids encoding no protein as a control (C; 3 µg), p73 (1.0 µg), Np73 (1.0 µg), and/or p300 (2.0 µg), together with the pGFP plasmid (200 ng), were introduced into H1299 cells (105/60-mm-diameter dish) using LipofectAmine (GIBCO-BRL); 32 h posttransfection, cells (100) expressing GFP were counted under a fluorescence microscope using a blind approach, with morphologically round cells (arrows) identified as apoptotic (A). (B) Statistical data (with standard error indicated by a bar above each column) from three independent assays. (C and D) Caspase 3 activation by wild-type but not N-terminus-deleted p73 is enhanced by p300. Transient transfection as described for panel A was conducted. Cells were harvested for caspase 3 activity analysis as described in Materials and Methods. (C) Representative result of the fluorescence graph of AMC released from Ac-DEVD-AMC substrates for one set of experiments with plasmids encoding no protein (curve B), Np73 (curve C), Np73 plus p300 (curve D), p73 (curve E), or p73 plus p300 (curve F). Curve A is a water control. Caspase 3 activity is presented in arbitrary units (A.U.) after normalization by a factor of 105. (D) Statistical values for caspase 3 activity in triplicate assays. (E) DNA fragmentation analysis of p73-induced apoptosis in H1299 cells was conducted as described in Materials and Methods; 10 µg of DNA was analyzed by electrophoresis on 2% agarose. Each lane represents the result for three 60-mm-diameter plates of cells. MW, molecular weight markers.

p73-mediated transcription and apoptosis are impaired to different degrees in p300- and CBP-deficient cells. It has been recently shown that p53 activation appears to require p300 but not CBP in response to DNA damage (88). Our results indicate that both p300 and CBP stimulate p73-mediated transcription (Fig. 4 and 5). To determine which of the coactivators is essential for p73-mediated transcription, cell lines expressing either active or inactive p300 or CBP ribozymes were used as described elsewhere (37, 88). In the active p300 or CBP ribozyme-expressing cells, p300 or CBP was hardly detectable by WB using anti-p300 or anti-CBP antibodies (Fig. 7A and C, lane p300R or CBPR), whereas these proteins were not affected in the inactive p300 or CBP ribozyme-expressing cells (lane p300Ria or CBPRia) compared with that in parental MCF-7 or H1299 cells (lane MCF-7 or H1299). p73 expression plasmids together with a luciferase reporter driven by the p53RE motif derived from the MDM2 promoter were transiently introduced into these cells as well as parental cells, and luciferase activity was measured (Fig. 7B). Consistent with the results above, luciferase activity was significantly elevated by p73 in the parental or inactive p300 or inactive CBP ribozyme-expressing MCF-7 cells (compare column 1 with columns 2, 3, and 5). By contrast, p73-dependent luciferase activity decreased by ~76% in the p300-deficient cells (column 4) and by ~53% in the CBP-deficient cells (column 6). The incomplete inhibition in either case was probably due to the existence of endogenous CBP or p300 (Fig. 7A, bottom panel). The reduction of p73-dependent transcription was not due to a difference in p73 expression, as p73 levels were equivalent in all cells transfected with Flag-p73 expression plasmids (Fig. 7B, middle panel). This result was also repeated with the p300- or CBP-deficient cell lines derived from H1299 (Zeng and Lu, unpublished data). The result suggests that both endogenous p300 and CBP proteins are utilized by p73 to execute transcription in cells, and lack of either of the coactivators impairs p73 transcriptional activity to a certain extent.

View larger version (42K): [in this window] [in a new window]   FIG. 7.   p73 transcription and apoptosis are impaired in p300- or CBP-deficient cells. p300- or CBP-deficient MCF-7 or H1299 cells were generated as described previously (88). (A) Cell lysates prepared from the indicated MCF cell lines were analyzed by WB with anti-p300 (RW109; Upstate Biotechnology) or anti-CBP antibodies. (B) The pCDNA3-Flag control vector or Flag-p73 was cotransfected with a luciferase reporter driven by an MDM2 promoter-derived p53RE motif into MCF-7 (columns 1 and 2), p300Ria (column 3), p300R (column 4), CBPRia (column 5), and CBPR (column 6) cells. pEGFP-C1 was included as transfection control (bottom panel). Luciferase activity was measured with a normalized protein concentration 24 h posttransfection. Cell lysates were also analyzed by WB with anti-Flag to detect Flag-p73 (middle panel) and anti-GFP antibodies (bottom panel). (C) WB analysis of p300 or CBP in p300- or CBP-deficient H1299 cell lines. (D) Apoptotic analysis of H1299 cell lines after transfection with plasmids as indicated, using the same approaches as described for Fig. 6. p300 RI, p300 RB, CBP RI, and CBP Rb stand for the p300Ria, p300R, CBPRia, and CBPR cell lines. p73 or mutant p73 denotes the wild-type p73 or N-terminally deleted p73. The result for the parental H1299 cells was similar to that for the p300Ria or CBPRia cell lines; thus, results for only the latter are presented here as a control.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

p300 and CBP have been shown to interact with a variety of transcriptional activators (72), including p53 (3, 26, 51), serving as a linker between these activators and the RNAPII transcriptional machinery. The study presented here further investigated whether this group of coactivators is also important for transcription mediated by the p53 homolog p73. This study demonstrates that p300 and CBP enhance p73-dependent transcription in vivo. Like p53, p73 interacted with p300 and CBP, as shown by in vitro protein-protein association assays (Fig. 2 and 3) or in vivo coimmunoprecipitation assays (Fig. 1). Unlike p53, which was originally found to bind to the C-terminal region of p300/CBP (3, 26, 51), the N-terminal domain of p73 bound to the N-terminal CH1-containing region of the coactivators (Fig. 2 and 5). Loss of this binding correlated with the defect in transcriptional activation by p73 (Fig. 5). Consistently, the N- but not the C-terminal fragments of p300, when overexpressed, inhibited p73-dependent transcription. By contrast, the C terminus of p300/CBP is crucial for transactivation by p53, as the transcriptionally inactive p53 mutant 22/23 (26, 52, 54) was still able to bind to the coactivator's N- but not C-terminal domain in vitro (data not shown; references 24 and 26). The difference between p73 and p53 in binding to distinct domains of p300/CBP was also observed in our recent study (91), in which MDM2, a cellular p53 inhibitor (60), selectively blocked the p73-p300 but not the p53-p300 interaction, as MDM2 itself bound to the p300 N terminus (aa 1 to 450) as well. However, binding of p53 to the N-terminal domain of p300/CBP was recently proposed to mediate MDM2-dependent p53 degradation (24), although the biological conditions under which p300 assists MDM2 to enhance p53 degradation are not known. Also, unlike p53, whose N-terminal domain (aa 1 to 45) was not absolutely essential for its apoptotic function (78), p73 appeared to require its N terminus for apoptosis (Fig. 6 and 7). This suggests that the transactivational activity of p73 may be closely related with its apoptosis function, although it remains possible that the N-terminal domain (aa 1 to 56) of p73 may induce apoptosis through a direct and transcription-independent pathway. Thus, these studies reveal that these two p53 family members share the same set of coactivators for their transactivational activities by targeting different domains of these partners.

It is interesting that p73 and p53 target different domains of p300/CBP (Fig. 2 and 5; references 24 and 26) for transactivation, despite the fact that the N termini of the two transcriptional activators are related (33). One interpretation for this difference could be that although p73 and p53 share an overall 29% identity in amino acid sequence in their N termini (33), the p73 N terminus is 16 residues longer than the p53 N terminus. This extra sequence in the middle of the p73 N terminus may cause some conformational variation that could, in turn, influence the manner by which p73 physically contacts p300 or CBP. This difference between p73 and p53 may serve to avoid a direct competition for the same set of coactivators between the activators of the same family within cells. Also, in line with the finding that p73 does not respond to some DNA-damaging reagents (33), this difference implies that p73 may be activated through a signaling pathway that requires the CH1 domain of p300/CBP, distinct from that for p53 activation.

One important question is whether p73 is also a substrate of the p300/CBP intrinsic acetylase, which acetylates histones (5, 63) and is vital for the biological function of these coactivators (32, 74). p53 was the first reported nonhistone protein and transcriptional activator shown to be acetylated by this family of coactivators (25). The acetylation of p53 by p300 or CBP stimulates its p53RE binding and transcriptional activities (25) in response to DNA damage (53, 68, 88). p73 requires a full-length p300 or CBP protein for synergistic activation of transcription (Fig. 5). This is reasonable because (i) the acetylase activity of p300/CBP, which maps to aa 1195-1810 (5, 63) of the coactivators, is required for transactivation in cells (25, 43, 79) and (ii) communication with the RNAPII transcriptional machinery important for p300/CBP functions is mediated through different regions of the coactivators (40, 61). Thus, it will be important to determine whether the p300/CBP-interacting p73 can be activated through acetylation as well.

It has not been resolved whether p300 and CBP contribute equivalently to transcriptional activation and thus cellular signaling mediated by different p300/CBP-interacting transcriptional activators in cells. One report showed that p300 and CBP can selectively stimulate transcription mediated by different human T-cell leukemia virus type 1 Tax mutants (7). Recently, p300 and CBP null mice have been generated by a gene knockout technique (86). The p300^/ or CBP^/ mice were embryonic lethal with severe proliferation defects, strongly demonstrating that these coactivators are essential for cell viability and development. Intriguingly, although retinoic acid receptor was reported to utilize both p300 and CBP as comediators (11, 34), retinoic acid receptor-dependent transcription was defective in the p300^/ but not in CBP^/ cells (86). This finding suggests that p300 and CBP may have some independent partners, which is consistent with the observation that p300 cannot compensate for the lack of CBP and vice versa (86). In agreement with this study is a recent report showing that p300 and CBP play distinct roles in retinoic acid-induced F9 cell phenotypes (38). p300 appears to be important for retinoic acid-induced differentiation, whereas CBP mediates retinoic acid-induced apoptosis (38). More recently, p53 was shown to be stabilized specifically by p300 but not CBP after ionizing irradiation using p300- or CBP-deficient MCF-7 cell lines (88). In contrast, using either the MCF-7 cell lines or p300- or CBP-deficient H1299 cells, we found that p73-mediated transcription was significantly impaired, though to different degrees, in the absence of either p300 or CBP (Fig. 7A and B). However, the inhibition of p73-mediated apoptosis was less dramatic in the CBP-deficient cells than in the p300-deficient cells (Fig. 7C and D). This difference suggests that p73-induced apoptosis may be regulated through mechanisms aside from its transcription activity and that p300 may be more important than CBP in regulating p73-dependent apoptosis. This question remains to be further investigated with the availability of cultured p300^/ and CBP^/ cell lines (86). Therefore, p300 and CBP may preferentially cooperate with p73 or p53 in mediating specific cellular processes.

In searching for p73 regulators (15, 91), it was found that p73 bound to p53's natural inhibitor MDM2 (60) and that this interaction reduced p73-mediated transcription in vivo. When overexpressed in cells, p73 was also able to induce the expression of MDM2 (91), which is a p53 target gene (82). Surprisingly, MDM2, though promoting p53 degradation (28, 45), failed to do so for the p73 protein (15, 91). Instead, it disrupted the interaction of p73 but not p53 with p300/CBP (91). These results indicate that MDM2 regulates p73 function through a mechanism distinct from that for p53 regulation, although p73 and p53 shares this MDM2 negative regulatory feedback loop. Recently, c-Abl was reported to up-regulate p73 but not p53 by phosphorylating its tyrosine residue 90 in response to  irradiation or cisplatin treatment (1, 22, 89). This is also different from p53, which is activated by ATM (ataxia telangiectasia mutated) through serine 15 phosphorylation after  irradiation (71, 73). Moreover, p73 does not appear to respond to UV-induced DNA damage (22, 33). Thus, despite the functional similarity between p73 and p53 in the downstream events (references 31, 33, and 91 and this study), p73 and p53 are regulated through different mechanisms in response to DNA damage signals. These differences may account for the distinct roles of p73 and p53 in cell growth and homeostasis. Identification of other upstream signals that regulate p73 functions is crucial for a better understanding its biological role.